Skip to content

T.R.F. pharma

Active Private limited companyfounded 2024active for 1 yearClos des Coyeûs 8, 4623 FléronKBO/BCE: BE 1017.867.223

Lifetime

2 annual accounts with figures on one time axis
peak of €42,395 in 2025
€42,395▲ 135%
peak of €33,200 in 2025
€33,200▲ 128%
peak of €46,597 in 2025
€46,597▲ 227%
€23,555▲ 373%
Board1 name since 2024
1 director
Documentsfilings and deeds
25-06-202636 days before the deadline
2025micro format
Gross margin from €18,074 to €42,395Result from €14,589 to €33,200Dividend €833Equity from €14,230 to €46,597Debts from €4,979 to €23,555

Key points

from the 2025 annual accounts

Equity

€46,597 ▲ 227%
14,2302024+33,200Profit-833Dividend46,5972025

T.R.F. pharma paid out €833 in dividends. That is 3% of the 2025 profit.

Turnover

≈ €190,000 estimated

The micro format states no turnover.

Investments

€1,895 5.8 times depreciation

Green is investment, beige is depreciation.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 11,279 companies had the same profile as T.R.F. pharma has now. Each dot stands for 29 companies, two years later.

96.6%
were still trading
2.6%
stopped another way
0.7%
went bankrupt
  • Micro
  • under 2 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 11,279 companies, not a prediction for T.R.F. pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 23-12-2024
  • founderdeed of 27-12-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:1017867223
Incorporation Founding capital of €500 · Founded by · appointed as director · published on 27-12-2024 · Gazette deed
First establishment Clos des Coyeûs 8, Fléron
All 5 events

Comparable companies

same main activity, similar in size and age
Company
T.R.F. pharma Fléron €70,151 €42,395 66.4% -
FARMACYZE Ostend €73,863 €42,761 66.9% -
Charlotte Slabbinck Oudenburg €72,938 €36,678 36.2% -
NED PHARMA Mons €74,278 €36,933 31.1% -
JDS Pharma La Louvière €63,805 €40,475 68.2% -
ELKE SEGERS Grimbergen €63,242 €37,590 73.5% -
ESPharma Anderlecht €74,825 €51,161 74.2% -

These companies have the same main activity as T.R.F. pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €63,200 and €74,800, founded between 2024 and 2025.

Official details

Source: KBO
Status
Active since 23-12-2024Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 1 other
Establishment unit
2.368.791.8644623 Fléron, since 23-12-2024
Financial year end
31 December
Peppol
Reachable since 17-09-2025
Company details

Annual accounts 2025

€70,151▲ 265%
Filing
Filed on 25-06-2026, 36 days before the end of the filing period
Financials

Insights on T.R.F. pharma

T.R.F. pharma has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €46,597 and a net result of €33,200.

Its solvency ranks better than 77% of 25,338 sector peers (NACE 47) in financial year 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about T.R.F. pharma

What is the company number of T.R.F. pharma?
The company number of T.R.F. pharma is 1017.867.223. The VAT number is the same number with BE in front: BE 1017.867.223.
Where is T.R.F. pharma based?
The registered office is at Clos des Coyeûs 8, 4623 Fléron.Company details
What does T.R.F. pharma do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of T.R.F. pharma?
T.R.F. pharma is a private limited company (BV).
When was T.R.F. pharma founded?
T.R.F. pharma was founded on 23-12-2024.
Is T.R.F. pharma still active?
Yes, T.R.F. pharma is an active enterprise in the KBO register.
What is the turnover of T.R.F. pharma?
The turnover in financial year 2025 is ≈ €190,000. This figure is estimated from the gross margin of €42,395 and 56 comparable companies (NACE 477). It probably lies between €110,000 and €350,000.Financials
Is T.R.F. pharma profitable?
In financial year 2025, T.R.F. pharma made a profit of €33,200.
Where can I find the annual accounts of T.R.F. pharma?
T.R.F. pharma filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of T.R.F. pharma due?
T.R.F. pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.